[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The First People's Hospital of Lianyungang\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":140},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,38,63,89,113],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":4},"100629925","association-between-intraoperative-mean-arterial-pressure-variability-and-postoperative-fatigue-in-patients-undergoing-laparoscopic-abdominal-surgery-100629925",false,"NCT07481006","Association Between Intraoperative Mean Arterial Pressure Variability and Postoperative Fatigue in Patients Undergoing Laparoscopic Abdominal Surgery","Inclusion Criteria:\n\n1. Age ≥ 18 years;\n2. ASA physical status I-III;\n3. Scheduled for elective laparoscopic abdominal surgery under general anesthesia.\n\nExclusion Criteria:\n\n1. Severe cardiac, hepatic, or renal insufficiency, or major neurological or psychiatric disorders;\n2. Known allergy to drugs used during the study;\n3. Participation in other clinical trials within the past 3 months;\n4. Unable to complete the required questionnaires or assessments;\n5. Surgery duration \\\u003C 60 minutes.","ALL","18 Years",{"count":18,"type":19},353,"ESTIMATED","7 Days","OBSERVATIONAL","This prospective cohort study aims to investigate the relationship between intraoperative mean arterial pressure (MAP) variability and postoperative fatigue syndrome (POFS) in elderly patients (≥18 years) undergoing laparoscopic abdominal surgery. The main research question is:\n\nDoes the degree of intraoperative MAP fluctuation correlate with postoperative fatigue in elderly patients?\n\nEligible patients scheduled for elective laparoscopic abdominal surgery under general anesthesia will have their intraoperative blood pressure variability recorded (generalized average real variability, G-ARV), and postoperative fatigue and recovery will be assessed on postoperative days 1, 3, and 7 using the Christensen fatigue scale.",[24,25],"Fatigue Symptom","Blood Pressure Variability","NOT_YET_RECRUITING","2026-03-20",{"date":29,"type":30},"2026-03-24","ACTUAL",{"date":32,"type":19},"2026-04-15",{"date":34,"type":19},"2026-12-31",{"name":36,"class":37},"The First People's Hospital of Lianyungang","OTHER",{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":46,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":4},"100614396","modified-mini-open-tlif-vs-traditional-open-tlif-100614396","NCT07279051","Modified Mini-Open TLIF vs Traditional Open TLIF","Modified Mini-Open TLIF Versus Traditional Open TLIF for Lumbar Spinal Stenosis : A Prospective, Randomized Controlled Trial","TLIF","Inclusion Criteria:\n\n* Patients aged between 18 and 80 years.\n* Presence of unilateral neurogenic claudication or radicular pain in the lower limbs, with failure to respond to at least 3 months of conservative treatment.\n* Presence of bilateral neurogenic claudication or radicular pain in the lower limbs, but with complete resolution of neurological symptoms in at least one lower limb during recumbency and an unremarkable physical examination, alongside failure to respond to at least 3 months of conservative treatment.\n* Radiologically confirmed single- or two-level lumbar spinal stenosis on MRI, with evidence of instability specifically at the stenotic level(s) on standing lateral radiographs.\n* The mMO-TLIF or TLIF surgical procedure is performed by the same lead surgeon at each participating investigational site.\n* Subjects voluntarily participate and provide written informed consent.\n\nExclusion Criteria:\n\n* Presence of bilateral radicular pain in the lower limbs that does not completely resolve at rest.\n* History of previous lumbar spine trauma or surgery.\n* Presence of spinal infection, tuberculosis, or tumor.\n* Contraindications to surgery, such as severe systemic medical diseases, coagulation disorders, severe active infectious diseases, or osteoporosis.\n* Significant intervertebral space collapse, presence of bony ankylosis, etc.\n* Incomplete data.","80 Years",{"count":48,"type":19},224,"INTERVENTIONAL",[51],"NA","This clinical study aims to find out if a modified mini-open spine surgery (modified mini-open transforaminal lumbar interbody fusion，mMO-TLIF) is as good as, or better than, the traditional open surgery (traditional transforaminal lumbar interbody fusion，traditional TLIF) for treating low back pain, leg pain, and walking difficulties caused by lumbar spinal stenosis with instability. The study will also look at the safety of both surgeries.\n\nIt is designed to answer these main questions:\n\nIs the mMO-TLIF surgery as good as the traditional TLIF surgery at improving patients' lower back function and quality of life? Does the mMO-TLIF surgery reduce blood loss during the operation and shorten hospital stays and recovery time? What medical problems (like infections or nerve injuries) might patients experience after having the mMO-TLIF surgery? Researchers will compare the results of the mMO-TLIF surgery group with the traditional TLIF surgery group to see which one works better.\n\nParticipants will:\n\nBe randomly assigned to receive either the mMO-TLIF minimally invasive surgery or the traditional TLIF open surgery.\n\nCome back to the hospital for check-ups before surgery, and then at 1 month, 3 months, 12 months and 24 months after surgery.\n\nDuring these check-ups, they will have physical exams, fill out questionnaires about their symptoms, dysfunction and quality of life, and get X-rays or CT scans to see how their bones are healing.",[54],"Spinal Stenosis Lumbar","2025-11-30",{"date":57,"type":30},"2025-12-12",{"date":59,"type":19},"2025-12-06",{"date":61,"type":19},"2028-05-01",{"name":36,"class":37},{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":70,"sex":15,"minAge":71,"maxAge":46,"enrollmentInfo":72,"targetDuration":4,"studyType":49,"phases":74,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":4},"100600332","ed90-of-teglidine-for-suppressing-lma-insertion-response-in-the-elderly-100600332","NCT07096115","ED90 of Teglidine for Suppressing LMA Insertion Response in the Elderly","The 90% Effective Dose of Taiglididine for Inhibiting Laryngeal Mask Insertion Response in Elderly Patients","Inclusion Criteria:\n\n1. Aged 65-80 years old.\n2. ASA physical status I-III.\n3. BMI 18-30 kg\u002Fm² (inclusive of critical values).\n4. Mallampati class I or II, mouth opening \\>2.5 cm.\n5. No abnormal airway or head\u002Fneck conditions.\n6. No risk of reflux or aspiration (e.g., full stomach, obesity, gastrointestinal obstruction).\n7. Expected surgery duration \\\u003C180 min.\n8. Scheduled for urological surgery requiring general anesthesia and laryngeal mask insertion.\n9. Voluntary participation with signed informed consent.\n\nExclusion Criteria:\n\nBaseline measurements: Severe hypertension (SBP \\>160 mmHg or DBP \\>100 mmHg), heart rate \\\u003C60 bpm or \\>100 bpm.\n\n2\\. History of long-term alcohol, sedative, or analgesic use; allergy to any study drugs.\n\n3\\. Severe dysfunction of vital organs (heart, lung, liver, kidney, nervous system), neuromuscular diseases, hyperthyroidism, obstructive sleep apnea syndrome.\n\n4\\. History of mental disorders or cognitive impairment severe enough to hinder understanding or cooperation with the study.\n\n5\\. Preoperative administration of sedative-hypnotics (including benzodiazepines and barbiturates).\n\n6\\. Upper respiratory tract infection within 1 month before surgery. 7. Participation in other clinical studies within the past 3 months. 8. Other conditions deemed unsuitable for the trial by the investigator.",true,"65 Years",{"count":73,"type":19},45,[51],"This research protocol aims to investigate the 90% effective dose (ED90) of taiglididine for inhibiting laryngeal mask insertion response in elderly patients. It is a non-randomized controlled trial using a biased coin design up-down method (BCD-UDM). A total of 54 elderly patients aged 65-80 years with ASA I-III, BMI 18-30 kg\u002Fm², and suitable for urological surgery under general anesthesia with laryngeal mask insertion will be enrolled. The first patient receives an intravenous injection of 1 mg taiglididine, followed by propofol and rocuronium. Subsequent doses of taiglididine are adjusted dynamically based on the previous patient's response: increasing by 0.1 mg if the insertion response is positive, or using BCD-UDM (11% probability to decrease by 0.1 mg, 89% to remain) if negative. The primary efficacy endpoint is the occurrence of laryngeal mask insertion response, while secondary endpoints include adverse events, vital sign changes, insertion success rate, and various time intervals. Safety is evaluated by monitoring vital signs. Statistical analysis will use SPSS 25.0 and R software to calculate ED90 and 95% confidence intervals via probit regression and bootstrap method, with at least 45 valid patients required to complete the trial.",[77],"Urological Surgery",[79,80],"Taiglididine","Elderly Patients","2025-07-24",{"date":83,"type":30},"2025-07-31",{"date":85,"type":19},"2025-09-01",{"date":87,"type":19},"2027-06-30",{"name":36,"class":37},{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":70,"sex":15,"minAge":71,"maxAge":46,"enrollmentInfo":96,"targetDuration":4,"studyType":49,"phases":98,"briefSummary":99,"conditions":100,"keywords":102,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":112,"locationsCount":4},"100599206","ciprofols-influence-on-lvot-vti-in-elderly-painless-colonoscopy-patients-100599206","NCT07081477","Ciprofol's Influence on LVOT VTI in Elderly Painless Colonoscopy Patients","Effect of Ciprofol on Left Ventricular Outflow Tract Velocity-Time Integral in Elderly Patients Undergoing Painless Colonoscopy","Inclusion Criteria:\n\n1. ASA classification I-III;\n2. Age ≥65 years and ≤80 years;\n3. BMI between 18-30 kg\u002Fm2 (including the threshold);\n4. Patients undergoing painless colonoscopy on an elective basis;\n5. Subjects voluntarily participated in this study and signed an informed consent form.\n\nExclusion Criteria:\n\n1. Those with respiratory depression or high risk of respiratory depression (e.g., sleep apnea syndrome, bronchial asthma, etc.);\n2. Suffering from major diseases such as severe hepatic and renal insufficiency, neurological and psychiatric systems;\n3. Suffering from severe arrhythmias such as severe aortic regurgitation, atrial fibrillation, tachycardia (heart rate \\> 120 beats\u002Fminute), atrioventricular block of degree II and above, myocardial infarction or unstable angina within 6 months before the examination, and NYHA classification grade II and above;\n4. Allergy to or abuse of any medication used in the study;\n5. Participation in another clinical trial within the last 3 months.",{"count":97,"type":19},120,[51],"1. Objective:\n\n   Primary: Compare the effect of Ciprofol vs Propofol on LVOT VTI at 2 minutes post-injection (T1) in elderly patients (≥65 years).\n\n   Secondary: Assess hypotension incidence, injection pain, nausea\u002Fvomiting, hypoxia (SpO₂≤90%), bradycardia (HR\\\u003C50 bpm), sedation success rate, induction\u002Frecovery times, procedure duration, drug doses, and patient satisfaction.\n2. Design:\n\n   Single-center, randomized, double-blind, controlled trial. Group C (Ciprofol):0.2-0.5 mg\u002Fkg IV induction (\\>30s injection). Group P (Propofol)::1-2 mg\u002Fkg IV induction (\\>30s injection). Rescue doses allowed (C: 0.1 mg\u002Fkg; P: 0.5 mg\u002Fkg; max 5 doses\u002F15 min).\n3. Participants:\n\n   N = 120 elderly patients (65-80 years, ASA I-III, BMI 18-30 kg\u002Fm²) scheduled for elective painless colonoscopy.\n\n   Exclusion: Significant cardiorespiratory, hepatic, renal, or neurological disorders; recent MI\u002Funstable angina (≤6 months); NYHA ≥II; drug allergies; recent trial participation.\n4. Key Assessments:\n\n   Primary Endpoint: LVOT VTI (via transthoracic echocardiography, TTE) at T1.\n\n   Secondary Endpoints:\n\n   Adverse events (hypotension, pain, nausea\u002Fvomiting, hypoxia, bradycardia, body movement, awareness).\n\n   Sedation success rate, induction\u002Frecovery times (MOAA\u002FS scale), procedure time. Drug doses (induction, total, vasoactive agents). Patient satisfaction (5-point scale). LVEF and IVC Collapse Index (TTE at T0, T1, T2). Safety: Vital signs (HR, BP, SpO₂).\n5. Statistical Analysis:\n\nSPSS 26.0; α=0.05. Methods: t-test, RM-ANOVA, Mann-Whitney U, Chi-square\u002FFisher's exact, rank-sum tests.\n\nThis study aims to determine whether Ciprofol provides superior hemodynamic stability (as measured by LVOT VTI) and fewer adverse effects compared to Propofol for sedation in elderly patients undergoing painless colonoscopy.",[101],"Ciprofol",[103,104,105],"Painless colonoscopy","Propofol","Left Ventricular Outflow Tract Velocity Time Integral","2025-07-15",{"date":108,"type":30},"2025-07-23",{"date":110,"type":19},"2025-08-25",{"date":87,"type":19},{"name":36,"class":37},{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":70,"sex":15,"minAge":16,"maxAge":46,"enrollmentInfo":120,"targetDuration":4,"studyType":49,"phases":122,"briefSummary":123,"conditions":124,"keywords":127,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":139},"100552669","srt-combined-with-anlotinib-for-the-treatment-of-brain-metastases-from-non-small-cell-lung-cancer-100552669","NCT06476093","SRT Combined With Anlotinib for the Treatment of Brain Metastases From Non-small Cell Lung Cancer","SRT Combined With Anlotinib for the Treatment of Brain Metastases From Non-small Cell Lung Cancer: a Single-arm, Prospective, Exploratory Clinical Study","Inclusion Criteria:\n\n1. Patients voluntarily participate in this study, sign informed consent, and demonstrate good compliance.\n2. Patients with histologically or pathologically confirmed EGFR wild-type and EGFR mutant non-small cell lung cancer resistant to treatment.\n3. The number of brain metastases is ≤ 5, and the patient has at least one assessable brain metastasis on imaging (RECIST 1.1). Additionally, the patient's physical condition allows for the completion of stereotactic radiosurgery.\n4. Age between 18-80 years, gender unspecified.\n5. ECOG performance status of 0 or 1; expected survival of no less than 3 months.\n6. Regardless of prior treatment, it is only required that concurrent oral administration of anlotinib during radiotherapy without intervention regarding subsequent treatment regimens.\n7. Oral administration of anlotinib including, but not limited to, third-line therapy.\n8. Good function of major organs, with laboratory test indicators meeting the following criteria:\n\n\u003C!-- -->\n\n1. Hematological examination:\n\n   1. Hemoglobin (Hb) ≥ 90g\u002FL (no blood transfusion within 14 days);\n   2. Absolute neutrophil count (ANC) ≥ 1.5×10\\^9\u002FL; total white blood cell count ≥ 3.5×10\\^9\u002FL;\n   3. Platelets (PLT) ≥ 100×10\\^9\u002FL;\n2. Blood biochemistry examination:\n\n   a、Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN (≤ 5 × ULN for liver metastasis\u002Fbone metastasis; ≤ 5 ULN for tumor bone metastasis); b、Total bilirubin (TBIL) ≤ 1.5 × ULN; c、Serum creatinine (Cr) ≤ 1.5×ULN or creatinine clearance rate ≥ 60 ml\u002Fmin;\n3. Coagulation function examination: Activated partial thromboplastin time (APTT), international normalized ratio (INR), prothrombin time (PT) ≤ 1.5×ULN.\n\n   Exclusion Criteria:\n   1. Squamous cell carcinoma patients (including adenosquamous carcinoma patients) should be excluded under the following conditions:\n\n      ① Cavitary lung cancer.\n\n      ② Patients who have had hemoptysis within the last month before the first dose and with a maximum daily hemoptysis of ≥2.5 mL, as well as other significant clinically relevant bleeding symptoms or those with a clear bleeding tendency combined with diseases\u002Fhistory.\n   2. Patients with diffuse pleural metastases, malignant pericardial effusion, or diffuse spinal cord involvement.\n   3. Patients with a history of other malignancies within 5 years (excluding cured basal cell carcinoma of the skin, prostate intraepithelial neoplasia, and cervical intraepithelial neoplasia).\n   4. Current presence of pulmonary pneumonia with CTCAE 5.0 grade ≥ 2.\n   5. Individuals with various factors that affect oral medication (such as dysphagia, gastrointestinal resection, chronic diarrhea, and intestinal obstruction).\n   6. Evidence of active bleeding, or unexplained persistent decrease in hemoglobin. Screening\u002Fenrollment should be postponed until bleeding stops and the investigator deems it safe.\n   7. Within the first 4 weeks before the initial dose, occurrence of any bleeding or hemorrhagic event ≥ Grade 3 according to CTCAE 5.0 standards; use of anticoagulants or vitamin K antagonists such as warfarin, heparin, or similar agents for treatment; under the condition that prothrombin time international normalized ratio (INR) ≤ 1.5, allowing the use of low-dose warfarin for prophylactic purposes (≤ 1mg\u002Fd), low-dose heparin (≤ 12,000 U\u002Fd), or low-dose aspirin (≤ 100mg\u002Fd).\n   8. Within the 4 weeks before the initial dose, the presence of unhealed wounds, fractures, active ulcers of the stomach and duodenum, ulcerative colitis, or active bleeding from unresected tumors, or conditions judged by the investigator to potentially cause gastrointestinal bleeding or perforation; or patients who have undergone major surgeries (excluding vascular access surgery).\n   9. Receipt of traditional Chinese medicine listed in the NMPA-approved drug instructions, which explicitly have indications for anti-tumor and lung cancer treatment (including compound Bupleurum capsules, Kangai injection, Conlear capsules\u002Finjections, Edaravone injections, Yadanzi oil injections\u002Fcapsules, Xiaocanping tablets\u002Finjections, HuaChanSu capsules), or immune modulating drugs (excluding local use for pleural effusion control) within 2 weeks before the initial dose.\n   10. History of organ or hematologic system transplantation.\n   11. Presence of clinically active diverticulitis, abdominal abscess, gastrointestinal obstruction.\n   12. Patients with severe and\u002For uncontrolled diseases, including:\n\n       * Patients with poorly controlled blood pressure (systolic blood pressure ≥150 mmHg, diastolic blood pressure ≥90mmHg);\n\n         * Occurrence of thrombotic events, ischemic stroke, myocardial infarction within 6 months of the first dose, congestive heart failure of Grade ≥2, or requiring treatment for arrhythmias (including QTc ≥480ms);\n\n           * Active or uncontrolled severe infections (grade ≥ 2 infection according to CTCAE 5.0), tuberculosis patients; ④ Known clinically significant liver disease history, including viral hepatitis, active HBV infection must be excluded for carriers of known hepatitis B virus (HBV) through positive HBV DNA (\\>2500 copies\u002FmL or \\>500 IU\u002FmL); known HCV infection and positive HCV RNA (\\>1×10\\^3 copies\u002FmL), or other decompensated liver disease, chronic hepatitis requiring antiviral therapy; ⑤ Positive HIV test, positive rapid plasma reagin (RPR) test for syphilis; ⑥ Poorly controlled diabetes (fasting blood glucose ≥10mmol\u002FL); ⑦ Urinalysis showing urinary protein ≥++, with confirmed 24-hour urinary protein quantification \\>1.0 g;\n   13. According to the judgment of the principal investigator, patients with other factors that may lead to the forced termination of this study, such as other serious illnesses (including mental illness) requiring combined treatment, significant laboratory abnormalities, family or social factors affecting patient safety, or data and sample collection.",{"count":121,"type":19},46,[51],"To evaluate the efficacy and safety of SRT combined with anlotinib in the treatment of limited brain metastases from non-small cell lung cancer.",[125,126],"Non-Small-Cell Lung Cancer","Brain Metastases",[128,129,125,126],"Anlotinib","SRT","RECRUITING","2024-06-24",{"date":133,"type":30},"2024-06-26",{"date":135,"type":19},"2024-07-01",{"date":137,"type":19},"2027-02-28",{"name":36,"class":37},1,""]